Skip to main content

Table 2 DI-MS/MS based on 20 important metabolites (VIP > 1.0) that contributed to separate 90-day non-survivors from survivors

From: Plasma lipid profiling for the prognosis of 90-day mortality, in-hospital mortality, ICU admission, and severity in bacterial community-acquired pneumonia (CAP)

Quantified metabolites by DI-MS/MS

 

Increased in non-survivors

Decreased in non-survivors

1

C5-DC (C6-OH) (glutaryl-l-carnitine)

Tryptophan

2

C3-DC (C4-OH) (malonyl carnitine)

LysoPC a C18:0

3

C5-M-DC (methylglutaryl-l-carnitine)

LysoPC a C18:1

4

C5:1 (tigyl-l-carnitine)

PC aa C38:5

5

Glycine

PC aa C38:4

6

C9 (lysophophatidylethanolamine, nonayl-l-carnitine)

LysoPC a C16:1

7

PC ae C40:2 (glycerol 3-phosphocholine)

 

8

PC aa C42:1 (lecithin, PC)

 

9

PC aa C40:3

 

10

PC ae C36:1

 

11

PC ae C38:1 (lecithin, phosphatidylcholine)

 

12

PC aa C40:1 (lecithin, PC)

 

13

PC aa C42:2 (lecithin, PC)

 

14

PC aa C40:2

 
  1. This shows the increased and decreased metabolites in non-survivors vs. survivors. The order of metabolites reflects the relative amount of change
Back to article page

Critical Care

ISSN: 1364-8535